The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer

Clinical Cancer Research

Volumn 7, Issue 4, 2001, Pages 831-838

  Buller, Richard E ^a   Lallas, Thomas A ^a   Shahin, Mark S ^a   Sood, Anil K ^a   Hatterman Zogg, Melanie ^a   Anderson, Barrie ^a   Sorosky, Joel I ^a   Kirby, Patricia A ^b  

^a Division of Gynecologic Oncology   (United States)

^b Departments of Pathology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; ARTICLE; CARCINOGENESIS; CPG ISLAND; DNA SEQUENCE; EXON; FEMALE; FRAMESHIFT MUTATION; GENE MUTATION; GERM LINE; HUMAN; HUMAN TISSUE; OVARY CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; SOMATIC CELL GENETICS; TUMOR SUPPRESSOR GENE;

BRCA1 PROTEIN; FEMALE; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM STAGING; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034896363     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. The p53 tumour suppressor gene
2. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
3. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies
4. The pattern of p53 mutations in Burkitt's lymphoma differs from that of solid tumors
5. Aflatoxin B1 induces the transversion of G-T in codon 249 of the p53 tumor suppressor gene in human hepatocytes
6. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53
7. Tandem double CC→TT mutations are produced by reactive oxygen species
8. Frequent p53 gene mutations and novel alleles in familial breast cancer
9. p53 mutations in BRCA1-associated familial breast cancer
10. Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations
11. p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours
12. Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers
13. BRCA-1 related papillary serous carcinoma of the peritoneum has a unique molecular pathogenesis
14. Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors
15. Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours
16. BRCA1 physically associates with p53 and stimulates its transcriptional activity
17. WAF1/CIP1 promoter
18. BRCA1 regulates p53-dependent gene expression
19. Maintenance of genomic integrity by p53: Complementary roles for activated and non-activated p53
20. Double indemnity: P53, BRCA and cancer
21. BRCA1, BRCA2, and DNA damage response: Collision or collusion?
22. BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner
23. BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells
24. The p53-mdm-2 autoregulatory feedback loop
25. Cell cycle regulation of BRCA1 messenger RNA in human breast epithelial cells
26. BRCA1 protein produces. Functional motifs
27. WAFI/CIP1
28. Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors
29. The tumor suppressor gene BRCA1 is required for embryonic cellular proliferation in the mouse
30. Targeted mutations of breast cancer susceptibility gene homologs in mice: Lethal phenotypes of Brcal, Brca2, Brca1/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos
31. Survival after breast cancer in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers
32. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1
33. Survival in familial, BRCA1-associated and BRCA2-associated epithelial ovarian cancer
34. Survival of BRCA1 breast and ovarian cancer patients: A population-based study from Southern Sweden
35. BRCA1. Pathology, and survival
36. The prognostic significance of p53 tumor suppressor gene alterations in ovarian cancer
37. Detection of BRCA1 mutations in women with early-onset ovarian cancer by use of the protein truncation test
38. Absence of significant germ line p53 mutations in ovarian cancer patients
39. An abundance of p53 null mutations in ovarian carcinoma
40. p53 allelotypes and enhanced detection of allelic loss in ovarian cancer: Lack of correlation with familial and clinical factors
41. Familial ovarian cancer
42. Optimization of PCR and electrophoresis conditions enhances mutation analysis of the BRCA1 gene
43. BRCA1 mutations in familial ovarian cancer
44. Field cancerization: Why late recurrent ovarian cancer isn't recurrent
45. 5-Methylcytosine as an endogenous mutation in the human LDL receptor and p53 genes
46. Multifactorial analysis of p53 alteration in human cancer: A review
47. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: A population-based study
48. Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions
49. Conditional mutation of Brcal in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation